The Filing Desk

Alvotech

ALVO · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

ALVO · Last close · November 19, 2026
$4.29

Alvotech's revenue rose 19.7% to $586 million in fiscal 2025. Its operating margin was 13.3%, down from 14.2% a year earlier. Free cash flow was −$115 million. The diluted share count rose 8.7%.

ALVOTECH Latest fiscal year ended December 31, 2025 20-F filed March 31, 2026 · 0001898416-26-000004 Updated
Revenue
$586M
19.7%
Operating margin
13.3%
0.9 pts
Net income
$28M
 
Free cash flow
−$115M
 
Return on capital
5.4%
12.3 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Alvotech is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What Alvotech does

Alvotech develops and makes biosimilar medicines, which are biological medicines highly similar to an existing approved biologic whose patent protection has ended. It says it focuses solely on biosimilars, for patients worldwide, and treats autoimmune, eye, respiratory and blood diseases and cancer.

It does the work in house, from development to manufacturing at its main site in Reykjavik, Iceland, and says it has invested over $2 billion in this platform. It does not sell most products itself. It licenses its biosimilars to commercial partners such as Teva, Advanz Pharma and Dr. Reddy's, and earns milestone payments and royalties on their sales.

It currently has five approved products and thirty more candidates in its pipeline. It competes with the companies that make the original drugs and with other biosimilar makers. It is also working with Dr. Reddy's on a biosimilar to Keytruda for global markets.

Its biggest risks, as it describes them

  • Developing and making biosimilars is slow, costly and uncertain, and its products may not win approval.
  • Its dependence on commercial partners to sell its products.
  • Doubt about its ability to keep operating without more financing, and the dilution that could follow.
  • Problems producing enough product, or interruptions at its manufacturers and service providers.
  • Claims that it or a partner infringes patents owned by others.
From Alvotech's annual report on Form 20-F, filed March 31, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments18661151172
Debt incl. finance leases4017659601,0691,299
Net debt (negative means net cash)3836989491,0171,127
Net debt to EBITDA———10.1x9.7x
Debt to equity—————
Interest coverage−2.0x−1.8x−1.3x0.2x0.5x
Current ratio1.1x1.4x0.8x2.4x1.9x
Quick ratio0.7x0.9x0.5x1.7x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 95 of 93 of 9
Rule of 40−367.7%376.2%0.2%
Altman Z''−11.06−4.98−3.91
Accruals ratio−26.9%0.5%5.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailPassPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsFailPassFail
F-score2 of 95 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Alvotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AlvotechFY2519.7%13.3%−19.6%5.4%9.7x3
TG TherapeuticsFY2587.3%20.0%−4.0%29.0%0.4x4Compare
ADMA BiologicsFY2519.6%37.5%5.5%39.5%−0.1x5Compare
Ascendis Pharma A/SFY2598.0%−18.9%———5Compare
RepligenFY2516.4%7.5%12.7%2.4%−1.7x—Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue67378391490586
Revenue growth—−44.8%125.8%10.1%435.6%19.7%
Gross profit—3719−69304351
Research and development148191181211171184
Operating income−138−236−346−3557078
Net income−170−102−514−552−23228
Diluted EPS (US$)−1.82−0.92−2.60−2.43−0.870.10
Diluted shares (millions)94111198227268291
Cash flow
Cash from operations−74−228−312−312−237−50
Capital expenditure82038335464
Free cash flow−82−249−350−345−290−115
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation—0101887
Balance sheet at fiscal year end
Cash and short-term investments3218661151172
Debt incl. finance leases—4017659601,0691,299
Total assets—5988289501,2211,487
Total liabilities—7341,3931,8831,6341,772
Shareholders' equity−867−136−564−932−413−284
Margins and ratios
Gross margin—100.0%22.8%−75.9%62.2%59.8%
Operating margin−206.5%−640.3%−417.2%−388.1%14.2%13.3%
Net margin−255.3%−276.0%−618.5%−603.4%−47.4%4.8%
Free cash flow margin−122.8%−676.1%−421.9%−377.8%−59.3%−19.6%
Rule of 40 (growth + FCF margin)—−720.9%−296.1%−367.7%376.2%0.2%
Return on capital——−143.5%—17.7%5.4%
Return on equity——————
Return on assets——−72.0%−62.0%−21.4%2.1%
Net debt to EBITDA————10.1x9.7x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Alvotech's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Alvotech.